T he risk of stroke in patients with atrial fibrillation (AF) is high, 1 and it increases in the presence of other risk factors such as advanced age, congestive heart failure, hypertension, diabetes mellitus, and especially previous ischemic stroke (IS) or transient ischemic attack (TIA).
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For decades, vitamin K antagonists have been used for stroke prevention in patients with AF and previous stroke/TIA. Vitamin K antagonists are effective in reducing the risk of IS when compared with placebo 7 ; however, they require regular monitoring of anticoagulation level and are subject to multiple drug-drug and food-drug interactions. More importantly, the risk of serious bleeding events, including intracranial hemorrhage (ICH) and fatal systemic bleeding in patients with AF, is increased. [7] [8] [9] Non-vitamin K oral anticoagulants (NOACs) have been available since 2009 and have been demonstrated to be at least as effective as warfarin in preventing stroke or systemic embolic events (SEE) in patients with AF, whereas significantly reducing ICH. [10] [11] [12] [13] A recent meta-analysis of the 4 major phase III trials 14 demonstrated relative reductions in ICH by 51% and mortality by 10% with NOACs compared with warfarin.
Among the NOACs, the directly acting, once-daily oral factor Xa inhibitor edoxaban, when compared with well-controlled warfarin, has been shown to be noninferior in preventing stroke or SEE and superior with lower rates of bleeding, ICH, cardiovascular mortality, and prespecified net clinical outcomes in the ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48) trial. 11 Furthermore, edoxaban markedly reduced hemorrhagic stroke, particularly in the first 6 months after randomization when compared with warfarin. 15 In the present analysis, we sought to compare efficacy and safety of once-daily edoxaban with warfarin in patients with AF and a history of previous IS and TIA.
Methods

Study Population and Protocol
ENGAGE AF-TIMI 48 was a randomized, double-blinded, doubledummy trial that compared 2-dose regimens of once-daily edoxaban (higher-dose edoxaban regimen [HDER] 60 mg and lower-dose edoxaban regimen 30 mg) with warfarin (international normalized ratio, 2.0-3.0; median time-in-therapeutic range, 68.4%) in 21 105 patients with AF over a median of 2.8 years. The dose of edoxaban was reduced by 50% for patients with creatinine clearance of <50 mL/min, body weight of ≤60 kg, or concomitant use of a strong P-gp inhibitor. The design and results of ENGAGE AF-TIMI 48 have been published previously. 11 Eligibility criteria included an age of ≥21 years, AF documented by electric tracing within the 12 months preceding randomization, a CHADS 2 score of ≥2, and planned anticoagulation therapy for the duration of the trial. Patients with previous ICH, severe impairment of renal function (creatinine clearance <30 mL/ min), increased bleeding risk, an alternate indication for anticoagulation, or requiring dual-antiplatelet therapy were excluded. As only the HDER is approved for the use by regulatory authorities worldwide, we focused on the comparison between HDER and warfarin in this article. We include results of the 7034 patients who were randomized to lower-dose edoxaban regimen in the online-only Data Supplement.
End Points
Primary end points in the ENGAGE AF-TIMI 48 trial were the composite of stroke (of any type) or SEE (efficacy) and major bleeding (safety). Detailed definitions of cerebrovascular end points have been published. 11, 15 IS was defined as an abrupt onset of focal neurological deficit caused by infarction with symptoms lasting for >24 hours or resulting in death in <24 hours. Nonfatal events lasting for <24 hours with complete neurological recovery were classified as TIAs. Primary hemorrhagic stroke included nontraumatic intraparenchymal, intraventricular, and subarachnoid hemorrhages. IS with hemorrhagic conversion was classified as a primary IS. ICH included subdural and epidural bleeds, as well as hemorrhagic stroke. All cerebrovascular events were adjudicated by independent stroke neurologists without the knowledge on the treatment assignment. Cardiovascular events, including acute coronary syndromes, SEE, death, and bleeding, were adjudicated by independent cardiologists without knowledge of treatment assignment.
Statistical Analysis
All efficacy analyses were performed in the intention-to-treat population and included all events after randomization. Bleeding events were analyzed in the safety population (all patients who took at least 1 dose of study drug) counting all hemorrhages that occurred through 30 days after the last dose. Hazard ratios (HRs) with 95% confidence intervals (CIs) comparing the relative efficacy and safety of edoxaban versus warfarin for the subgroup were calculated with the Cox proportional hazards models with treatment as a covariate along with the stratification factors of CHADS 2 score and dose-adjustment status. Models were also constructed that evaluated the interaction between randomized treatment group and subgroups stratified by a history of IS/TIA before randomization. HRs with 95% CIs comparing patients with versus without a previous history of stroke/TIA were calculated using an adjusted Cox proportional hazards model, which included sex, age, race, geographic region, body mass index, smoking status, alcohol use, AF pattern, hypertension, coronary artery disease, dyslipidemia, congestive heart failure, diabetes mellitus, increased risk of falling, hepatic disease, neuropsychiatric disease, previous non-ICH bleed, the use of antiplatelet or nonsteroid anti-inflammatory drugs at randomization, and creatinine clearance at randomization. We also reported absolute risk differences of event rates per 10 000 patient-years between the edoxaban and the warfarin arms (calculated as the annualized event rate in the warfarin group minus the rate in the edoxaban group ×10 000). Analyses were performed independently by the TIMI Study Group using Stata v12.1 and SAS v9.2.
Results
There were 5973 (28.3%) patients with a history of IS and TIA enrolled in ENGAGE AF-TIMI 48 trial, of whom 67% had CHADS 2 4 to 6 (compared with 5.1% in those without previous IS/TIA) and 36% were aged ≥75 years (Table 1) . A history of previous IS/TIA was highest among patients enrolled from the Asia-Pacific/South Africa region (39.2%) and lowest among patients enrolled from the North America region (23.6%). A greater prevalence of congestive heart failure, diabetes mellitus, and elevated body mass index was present among patients without a history of IS/TIA (P<0.001). This observation may be explained by the protocol requirement for a minimum CHADS 2 of 2 for trial participation; hence, patients without previous IS/TIA were enriched for other stroke risk factors. More patients with previous stroke/ TIA had used vitamin K antagonist for at least 60 consecutive days before randomization (60.3% versus 58.4%, P=0.010).
Efficacy Outcomes
Overall, there was a higher rate of stroke/SEE among patients with previous IS/TIA when compared with those without (2.83% versus 1.42% per year; adjusted HR, 1.97; 95% CI, 1.73-2.24; P<0.001; Table I in the online-only Data Supplement). This difference was driven mainly by a higher annual rate of primary IS (2.35% versus 1.07%; adjusted HR, 2.19; 95% CI, 1.89-2.53) among patients with previous IS/TIA, whereas annual rates of primary hemorrhagic stroke were numerically, but not significantly higher (0.37% versus 0.27%; P=0.12). The adjusted risks for other stroke and efficacy outcomes were significantly increased among patients with previous IS/TIA (Table I in the online-only Data Supplement).
Analyses of the relative efficacy of HDER when compared with warfarin stratified by a previous history of stroke or TIA demonstrated no evidence of effect modification (Table 2) . Among patients with previous IS/TIA, the HRs for HDER versus warfarin were 0.86 for stroke/SEE, 0.96 for primary IS, and 0.52 for primary hemorrhagic stroke (Figure 1 ). The 2-fold higher rate of stroke/SEE among patients with a previous IS/TIA translated into a numerically, but not significantly, larger absolute difference favoring edoxaban versus warfarin among patients with a previous IS/TIA (41 [−22 to 104] per 10 000 patient-years) compared with patients without a previous IS/TIA (17 [−11, 44]; Table 2 ).
As was observed in the overall population in the main trial, in the subgroup with previous IS/TIA, HDER significantly reduced cardiovascular death (HR, 0.79) and various composite end points that combined stroke and death, whereas there was a strong trend toward a reduction in Table 2 ). Patients without a history of IS/TIA experienced qualitatively similar benefits with HDER versus warfarin ( Table 2 ). The absolute risk differences per 10 000 patient-years favoring edoxaban were numerically, but not significantly, greater among patients with versus without a previous IS for all 14 efficacy end points shown in Table 2 .
Safety Outcomes
Annual rates of major hemorrhage (3.03% versus 2.64%; adjusted HR, 1.25; 95% CI, 1.10-1.41; P<0.001) and ICH (0.70% versus 0.40%; adjusted HR, 1.62; 95% CI, 1.22-2.14; P<0.001) were higher in patients with previous IS/TIA than in those without. Other safety outcomes were also significantly more frequent in patients with previous IS/TIA (Table II in the online-only Data Supplement), with the exception of fatal bleeding that had similar rates in patients with versus without previous IS/TIA.
There was no evidence of a significant treatment-subgroup interaction in the comparison of HDER versus warfarin for key safety outcomes when patients were stratified by a previous history of stroke/TIA ( Figure 2 ), as well as significantly reducing life-threatening bleeding, major or clinically relevant nonmajor bleeding, and any bleeding (Table 3) . Absolute risk differences between HDER and warfarin for most bleeding events were similar, regardless of the presence or the absence of previous IS/TIA, with the exception of fatal bleeding. There were 25 (2-47) versus 14 (0-27) fewer fatal bleeds per 10 000 patient-years with edoxaban among those with versus without a previous IS/TIA, respectively.
In addition, as in the total trial population, among patients with previous IS/TIA, HDER reduced various net outcomes that included stroke, death, and bleeding (Table 3 ). This included a significant (P=0.003) reduction by 21% in a net outcome that included 3 of the most serious events-death, disabling stroke, or life-threatening bleeding. In patients without previous IS/TIA, the safety profile of HDER was qualitatively similar and also superior to warfarin (Table 3 ). In terms of absolute risk reductions, patients with a previous IS/ TIA randomized to edoxaban had 4-to 8-fold larger absolute reductions in death or disabling stroke (100 
Lower-Dose Edoxaban Versus Warfarin
Data comparing the lower-dose edoxaban regimen with warfarin are shown in the Tables III and IV 
Discussion
We observed, in this prospectively planned subgroup analysis of the phase III randomized ENGAGE AF-TIMI 48 clinical trial, that patients with previous IS stroke/TIA were at high risk of recurrent stroke and bleeding related to anticoagulation, consistent with previous observations. [4] [5] [6] [7] [8] [9] Therefore, testing the effect of novel therapeutics, such as edoxaban, in this subgroup is relevant to clinical practice. As such, we found that patients with a previous IS/TIA experienced a similar relative, but greater absolute benefit, when compared with patients with no previous IS/TIA, when treated with the oral direct factor Xa inhibitor edoxaban instead of warfarin.
When compared with patients treated with warfarin, patients with previous IS/TIA randomized to HDER had significantly lower rates of primary hemorrhagic stroke (48% relative reduction), cardiovascular death (21%), major adverse cardiac events (16%), and various composite outcomes such as all-cause stroke/death/SEE (17%) and cardiovascular death/stroke/SEE (18%). These efficacy metrics are supported and, in part, might be explained by the favorable safety profile of the HDER in patients with previous IS/TIA demonstrating significant reduction in the rates of ICH (43% relative reduction), major and clinically significant nonmajor bleeding (15%), fatal (60%), life-threatening (39%), or any (16%) bleeding, as well as the net clinical end point outcomes such as death/stroke/SEE/major bleed (16%), death or disabling stroke (18%), death or disabling stroke or life-threatening bleed (21%), and death or stroke or ICH (20%). In addition, all-cause death was reduced by 16% (P=0.051) in patients with previous IS/TIA treated with HDER versus warfarin. There are limited data on the NOAC use in patient populations at high risk for recurrent events, including those with previous IS/TIA. With exception of a recent analysis of rivaroxaban use in a number of higher-risk populations from the ROCKET-AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) trial, 16 our study is the first to provide the dedicated data in support of safety and efficacy of NOAC use in patients with previous IS/TIA.
Previous data 11, 14, 15 indicate that the reduction of hemorrhagic event rates (particularly intracranial bleeding) represents this primary clinical benefit of edoxaban over warfarin. In this analysis, the rates of ischemic and hemorrhagic events were higher in the patients with previous IS/TIA than in those without a previous IS/TIA, despite having fewer traditional stroke risk factors. This observation is not entirely unexpected because patients with AF are thought to have a distinct pathophysiology of stroke related to thromboembolism, rather than the mechanisms of stroke related to atherosclerosis of cerebral vessels. 17, 18 Additional risk of stroke recurrence in patients with AF might come from insufficient anticoagulation, or ineffective control of other vascular pathologies. Regarding the increased risk of hemorrhagic events in patients with AF with previous IS/TIA, there are several factors that might be contributory. First, older individuals and those with supratherapeutic anticoagulation with warfarin have higher risks of intracerebral and subdural hemorrhage. 19 Furthermore, a history of cerebrovascular disease is an independent predictor of intracerebral hematoma (odds ratio, 3.1; 95% CI, 1.7-5.6) among outpatients taking warfarin, 19 underscoring the potential mechanisms by which previous stroke might increase the risk of intracerebral hemorrhage including (1) underlying small cerebral vessel disease such as cerebral amyloid angiopathy 20 or (2) the presence of the subclinical (silent) or occult brain infarcts that may predispose to brain hemorrhage. 21 When warfarin-related intracerebral hemorrhage occurs, stroke mortality rate doubles in a dose-dependent manner, 22 likely related to the large size of hematoma. 23 Thus, preventing hemorrhagic cerebrovascular events is of paramount importance for those patients who require anticoagulation because of high risk of recurrent embolic stroke. In this analysis, patients with previous IS/TIA randomized to HDER experienced similar protection from arterial thromboembolism and death when compared with well-managed warfarin (median time-in-therapeutic range 68.4%) and superior protection from primary hemorrhagic stroke and ICH, similar to the overall ENGAGE AF-TIMI 48 cohort. 11 However, because patients with previous IS/TIA were at a substantially higher risk of recurrent stroke, ICH, and death compared with those without a history of stroke/TIA, the absolute risk reductions favoring edoxaban were numerically magnified by a factor of 2-to 8-fold for several cerebrovascular and mortality end points, including stroke/SEE, all-cause mortality, cardiovascular death, and a variety of composite end points in those with previous cerebrovascular events. These data highlight an additional advantage of edoxaban's favorable safety profile in patients with previous IS/TIA, which along with the facilitation of patient compliance of once-daily dosing without need for routine monitoring, make edoxaban an attractive option for anticoagulation among patients with AF and a previous cerebrovascular ischemic event.
Conclusions
Patients with history of IS and TIA represent a vulnerable population of patients with AF, who are highly prone for recurrent cerebrovascular events. In this prespecified analysis of a large, randomized double-blind trial of patients with AF, we demonstrated that on account of higher ischemic and hemorrhagic event rates, patients with AF and a history of previous IS/TIA have generally greater absolute benefits from oncedaily edoxaban versus well-managed warfarin, when compared with AF patients without a history of previous IS/TIA. Furthermore, the superior safety profile of edoxaban extends to these patients with previous stroke/TIA, all of whom have a strong indication for anticoagulation for secondary stroke prevention. 
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